New study aims to predict immunotherapy response in lung cancer patients before surgery

NCT ID NCT05965557

Recruiting now Knowledge-focused Sponsor: Geneplus-Beijing Co. Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 01, 2026 · Updated 3 times

Summary

This study is looking for genetic clues that might tell doctors whether immunotherapy will work well before lung cancer surgery. Researchers will collect blood and tumor samples from 100 people with stage II-IIIB non-small cell lung cancer. They will test for two types of genetic markers: homologous recombination deficiency (HRD) and circulating tumor DNA (ctDNA). The goal is to see if these markers can predict how well the cancer responds to treatment and whether it stays away for two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors predict which lung cancer patients will benefit from immunotherapy before surgery, leading to more personalized treatment.
What could go wrong: This is an early-stage biomarker study, not a treatment trial. The findings may not lead to immediate changes in care, and the genetic markers being studied may not prove reliable in larger groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER

Contacts and locations

Locations

Shanghai Chest Hospital
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.